David Goodrich

Distinguished Professor of Oncology

Roswell Park Comprehensive Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Advanced prostate cancer remains a leading cause of cancer-related death among men due to disease progression in nearly all patients on standard-of-care therapy targeting the androgen receptor. An important mechanism driving therapeutic resistance is lineage plasticity, which enables prostate cancer cells to reprogram into lineage variants no longer dependent on androgen receptor signaling. As inhibitors of the histone methyltransferase enhancer of zeste homolog 2 (EZH2) are being evaluated clinically for the treatment of advanced prostate cancer, we investigated in this study how EZH2 affects prostate cancer lineage plasticity. Data from genetically engineered mice and human clinical samples demonstrated that genetic or pharmacologic suppression of EZH2 altered chromatin to expand active transcription factor programs. These changes in gene expression during prostate cancer progression increased the diversity of prostate cancer lineage variants that arose. EZH2 suppression did not inhibit disease progression nor therapeutic resistance in this context. These findings advance the current understanding of prostate cancer lineage plasticity and suggest that EZH2 inhibitors may be less effective in treating prostate cancer prone to lineage plasticity. Significance: EZH2 suppression diversifies prostate cancer lineage plasticity, which has implications for EZH2-targeted therapies that are being evaluated for prostate cancer treatment. See related commentary by Thienger et al., p. 827

Year:

2026

Epidemiologic studies suggest that diet can affect the incidence, progression, and response to treatment in multiple cancers, including prostate cancer. In this study, we investigated the use of dietary interventions, specifically caloric or protein restriction, in combination with antiandrogen therapy as a treatment for prostate cancer. Caloric restriction through alternate-day fasting (ADF) reduced androgen receptor (AR) expression and signaling. This reduction in AR enhanced the antitumor activity of the AR antagonist enzalutamide in multiple mouse models of prostate cancer. Mechanistic studies revealed that nutrient starvation via ADF predominantly decreased AR mRNA translation at the elongation stage due to AA limitation. Pharmacologic agents that similarly impair translation elongation and promote ribosome collisions mimicked the AR translation reduction observed with ADF. Overall, these findings suggest that AA limitation through ADF impairs translation elongation in prostate cancer, to which AR mRNA translation is susceptible, leading to a reduction in AR protein levels and enhancing AR-targeted therapy. Significance: Fasting-induced caloric restriction reduces androgen receptor translation and enhances the activity of enzalutamide, suggesting that dietary intervention could be an effective strategy to enhance prostate cancer sensitivity to antiandrogen therapy. See related commentary by Anzules et al., p. 4045

Year:

2025

Differentially expressed genes from RNAseq of B6MyC-CaP tumors, IPA upstream regulator analysis and AR-dependent genes, IPA metabolic and signaling pathways, and rat probasin promoter region containing ARE

Year:

2025

Particle size distributions obtained by Zeta View of sEVs derived from WT and TR mouse plasma (A-B) Zetaview Nanoparticle tracking analysis measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) WT or (B) TR mouse plasma.

Year:

2025

Particle size distributions obtained by Nanoparticle tracking analysis (NTA) of sEVs derived from β1 FF or β1 FF TR mouse plasma (A-B) NTA measurement of size distribution and concentration of iodixanol density gradient isolated md-sEVs derived from (A) β1 FF or (B) β1 FF TR mouse plasma.

Year:

2025

Validation of STEAP1 antibody specificity using siRNA (A) Immunoblotting (IB) of STEAP1, androgen receptor (AR), and β-Actin expression in C4-2 cells transfected with a SMARTpool siRNA against STEAP1 (siSTEAP1) or scramble siRNA (scramble) for 48 (right) and 96 hours (left). (B) IB of STEAP2 and (C) STEAP4 expression in C4-2 cells transfected with SMARTpool siRNA against STEAP1 (siSTEAP1) or scrambled siRNA (siScramble) for 48 hours. Vinculin is used as loading control.

Year:

2025

STEAP expression changes with DHT dose response Relative mRNA expression of (A) STEAP2 and STEAP4 in LNCaP cells and (B) STEAP1, STEAP2, STEAP4 and KLK3 expression in C42 cells treated with 0 nM (DMSO), 0.1 nM, 1 nM, and 10 nM DHT for 24 hours in regular growth or CSS conditions. P-values were calculated using two-way ANOVA followed by post-hoc Tukey test for multiple comparisons.

Year:

2025

The six-transmembrane epithelial antigen of the prostate (STEAP; STEAP1 and STEAP2) metalloreductases are therapeutic targets for advanced prostate cancer, and their expression has been linked to androgen receptor (AR) signaling; however, the regulatory mechanism and functions of STEAP1 and STEAP2 in prostate cancer progression remain elusive. In this study, we explore how in vitro androgen modulation and AR inhibition influence the expression of STEAP family members in cell lines with varying reliance on androgen signaling. Our data show that in response to androgen deprivation, STEAP1 and STEAP2 exhibit elevated transcript levels, whereas STEAP4 levels are reduced, mirroring the expression profile of kallikrein-related peptidase 3 ( KLK3 ). As STEAP1 and STEAP2 are implicated in the exocytic pathway, we evaluated expression profiles in small extracellular vesicles (sEV) released from prostate cancer cells and in circulating sEVs. STEAP1, but not STEAP2, is upregulated in sEVs from AR-negative cells, which express low cellular STEAP1, and AR-positive cells, which express high cellular STEAP1. These results indicate selective packaging of STEAP1 in prostate cancer cell–derived sEVs, irrespective of AR status and cellular STEAP1 expression levels. Finally, ex vivo analysis of circulating sEVs from genetically engineered mice carrying prostate cancer shows that STEAP1 is found in the sEV cargo and that its levels are independent of protumorigenic β1 integrin expression in the prostatic epithelium. Implications: Understanding how androgen dependence affects STEAP1 expression in both tumor cells and sEVs across distinct disease stages will illuminate the clinical benefit of combinatorial AR and STEAP1-directed therapies and inform the optimal placement of STEAP1 targeting within the prostate cancer disease continuum.

Year:

2025

STEAP mRNA expression in response to AR antagonist Relative mRNA expression of STEAP1, STEAP2, STEAP4 and KLK3 in (A) LNCaP cells, (B) C4-2 cells and (C) 22Rv1 cells treated with indicated doses of enzalutamide for 24 hours in regular growth or CSS conditions. KLK3 is the positive control for AR signaling response. Experiments were performed in n = 3 or n = 4. The values are presented as replicates with error bars representing mean ± SEM. P-values were calculated using Two-Way ANOVA with a 95% confidence interval threshold followed by post-hoc Dunnett test for multiple comparisons.

Year:

2025

Correlation of STEAP1 expression with AR and AR target genes in primary and metastatic PCa cohorts Gene expression correlations of STEAP1, AR and canonical AR target genes KLK2, KLK3, KLK15, NKX3-1 and TMPRSS2. mRNA expression from Z-scores quantified by RNA Seq V2 RSEM for primary and FPKM for metastatic. (A) Primary Prostate Adenocarcinoma (TCGA Firehose Legacy) and (B) Metastatic Prostate Adenocarcinoma (SU2C/PCF Dream Team, 2019). (C) RNA-sequencing values from 210 mCRPC patient biopsies. Correlations between Z-scores of AR activity (top row) and KLK3 (bottom row) with STEAP1 and STEAP2. AR activity was measured as the mean Z-score of 7 AR target genes.

Year:

2025

Collaborators (14)

Luigi Fontana

Leonard P Ullmann Chair in Translational Metabolism

University of Sydney

AUSTRALIA
View details

Paloma Cejas

Head of Innovation/Director

Dana-Farber Cancer Institute

UNITED STATES
View details

Mark Long

Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Prashant K Singh

Director, Genomics Shared Resource

Roswell Park Comprehensive Cancer Center Department of Cancer Genetics

UNITED STATES
View details

Maria Tsompana

Research Assistant Professor

University at Buffalo

UNITED STATES
View details

Jianmin Wang

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Lucia Languino

Prof

Thomas Jefferson University

UNITED STATES
View details

Ricardo Santos

Thomas Jefferson University

UNITED STATES
View details

Kirk Staschke

Member

Indiana University School of Medicine

UNITED STATES
View details

Kevin Kelly

Professor, Associate Director of Research, SKCC

Thomas Jefferson University

UNITED STATES
View details

Ronald C Wek

Professor

Indiana University School of Medicine

UNITED STATES
View details

Alessandro Fatatis

Drexel University College of Medicine

UNITED STATES
View details

Jagannath Misra

Assistant Research Professor

Indiana University School of Medicine

UNITED STATES
View details

Matthew Schiewer

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details